ResMed (ASX: RMD) — Stock Profile

ResMed develops, manufactures, and markets medical devices and cloud-based software applications for the diagnosis, treatment, and management of respiratory disorders, serving customers across the United States and internationally. The company operates through two segments, Sleep and Breathing Health and Residential Care Software, addressing clinical and home-based care settings through an integrated combination of hardware and digital health tools.

On the device and monitoring side, ResMed offers diagnostic products such as ApneaLink Air, NightOwl, and EasyCare Tx for sleep apnea assessment, alongside cloud-based platforms including AirView for remote patient monitoring and myAir for personalized therapy management. Its software portfolio spans several brands serving post-acute and home-based care providers, with Brightree supporting home medical equipment and pharmacy organizations, HEALTHCAREfirst serving home health and hospice agencies, MatrixCare providing electronic health record solutions for skilled nursing and senior living communities, and MEDIFOX DAN catering to residential and home health providers in additional markets. Founded in 1989, ResMed is headquartered in San Diego, California.